[Falls Church, Virginia, September 12, 2024] – Magna Labs, a leading innovator in bioinformatics quality assurance (QA) solutions, is pleased to announce that it has been awarded a Technology Commercialization Grant from the Virginia Innovation Partnership Corporation (VIPC). This funding will accelerate the development of Magna Labs’ technology, Miqa, an automated, no-code quality assurance (QA) software platform that streamlines bioinformatics pipeline validation for precision medicine and clinical genomics research.
Miqa addresses critical challenges in the bioinformatics field by providing an accessible, automated solution for validating the software pipelines used in genomic research. As the precision medicine industry grows, ensuring the reliability and accuracy of bioinformatic data has become increasingly important. Miqa empowers research teams with no-code tools that enhance the reproducibility and quality of their data without requiring advanced technical expertise.
“We are proud to award Magna Labs this Technology Commercialization Grant to support the continued development of their innovative QA software,” said Sean Mallon, VIPC’s Vice President for Commercialization. “Magna Labs’ Miqa platform has the potential to significantly impact precision medicine and genomics by improving the accuracy and efficiency of data validation. We look forward to seeing how this technology advances.” (source: EIN Presswire).
The grant will enable Magna Labs to further enhance Miqa’s capabilities, including expanding its cloud functionality and improving support for bioinformatic teams working in both research and clinical environments. By integrating automation and software engineering best practices, Miqa helps ensure that software used in genomic studies is reliable, reproducible, and ready for the challenges of precision medicine.
This funding will also help Magna Labs scale its platform to meet the evolving demands of the industry, positioning the company at the forefront of innovation in bioinformatics software validation.
For more information about Magna Labs and its no-code QA platform, Miqa, visit www.magnalabs.co.
Magna Labs is a pioneering bioinformatics company focused on automating quality assurance (QA) processes for genomic and computational biology research. Its no-code platform, Miqa, empowers researchers and bioinformaticians to validate software pipelines with greater ease, efficiency, and accuracy, ensuring reproducibility and compliance in data-driven science. Magna Labs is committed to advancing innovation and standardization in bioinformatics and precision medicine.
